Myeloid Growth Factors

Restricted access

Febrile neutropenia, a common side effect of myelosuppressive chemotherapy in patients with cancer, can result in prolonged hospitalization and broad-spectrum antibiotic use, often prompting treatment delays or dose reductions of drug regimens. Prophylactic use of myeloid growth factors (mainly the colony-stimulating factors filgrastim and pegfilgrastim) in patients of heightened risk can reduce the severity and duration of febrile neutropenia. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Myeloid Growth Factors provide recommendations on the use of these agents mainly in the oncology setting based on clinical evidence and expert consensus. This version includes revisions surrounding the issue of timing of pegfilgrastim administration. It also includes new sections on tbo-filgrastim, a recently approved agent that is biologically similar to filgrastim, and the role of myeloid growth factors in the hematopoietic cell transplant setting

  • 1.

    Lyman GH, Kuderer NM. Epidemiology of febrile neutropenia. Support Cancer Ther 2003;1:2335.

  • 2.

    Dale DC, McCarter GC, Crawford J, Lyman GH. Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. J Natl Compr Canc Netw 2003;1:440454.

    • Search Google Scholar
    • Export Citation
  • 3.

    Dale DC. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs 2002;62(Suppl 1):115.

  • 4.

    Fortner BV, Schwartzberg L, Tauer K. Impact of chemotherapy-induced neutropenia on quality of life: a prospective pilot investigation. Support Care Cancer 2005;13:522528.

    • Search Google Scholar
    • Export Citation
  • 5.

    Gisselbrecht C, Haioun C, Lepage E. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin’s lymphoma: factors influencing chemotherapy administration. Groupe d’Etude des Lymphomes de l’Adulte. Leuk Lymphoma 1997;25:289300.

    • Search Google Scholar
    • Export Citation
  • 6.

    Timmer-Bonte JN, de Boo TM, Smit HJ. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. J Clin Oncol 2005;23:79747984.

    • Search Google Scholar
    • Export Citation
  • 7.

    Trillet-Lenoir V, Green J, Manegold C. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29A:319324.

    • Search Google Scholar
    • Export Citation
  • 8.

    Vogel CL, Wojtukiewicz MZ, Carroll RR. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005;23:11781184.

    • Search Google Scholar
    • Export Citation
  • 9.

    Bui BN, Chevallier B, Chevreau C. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. J Clin Oncol 1995;13:26292636.

    • Search Google Scholar
    • Export Citation
  • 10.

    Chevallier B, Chollet P, Merrouche Y. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 1995;13:15641571.

    • Search Google Scholar
    • Export Citation
  • 11.

    Crawford J, Ozer H, Stoller R. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164170.

    • Search Google Scholar
    • Export Citation
  • 12.

    Gatzemeier U, Kleisbauer JP, Drings P. Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a phase III, multicenter, randomized study. Am J Clin Oncol 2000;23:393400.

    • Search Google Scholar
    • Export Citation
  • 13.

    Muhonen T, Jantunen I, Pertovaara H. Prophylactic filgrastim (G-CSF) during mitomycin-C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer. A randomized study. Am J Clin Oncol 1996;19:232234.

    • Search Google Scholar
    • Export Citation
  • 14.

    Osby E, Hagberg H, Kvaloy S. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 2003;101:38403848.

    • Search Google Scholar
    • Export Citation
  • 15.

    Pettengell R, Gurney H, Radford JA. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin’s lymphoma: a randomized controlled trial. Blood 1992;80:14301436.

    • Search Google Scholar
    • Export Citation
  • 16.

    Zinzani PL, Pavone E, Storti S. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin’s lymphoma. Blood 1997;89:39743979.

    • Search Google Scholar
    • Export Citation
  • 17.

    Doorduijn JK, van der Holt B, van Imhoff GW. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin’s lymphoma. J Clin Oncol 2003;21:30413050.

    • Search Google Scholar
    • Export Citation
  • 18.

    Fossa SD, Kaye SB, Mead GM. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 1998;16:716724.

    • Search Google Scholar
    • Export Citation
  • 19.

    Citron ML, Berry DA, Cirrincione C. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:14311439.

    • Search Google Scholar
    • Export Citation
  • 20.

    Pfreundschuh M, Trumper L, Kloess M. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004;104:634641.

    • Search Google Scholar
    • Export Citation
  • 21.

    Bohlius J, Reiser M, Schwarzer G, Engert A. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev 2004:CD003189.

    • Search Google Scholar
    • Export Citation
  • 22.

    Sung L, Nathan PC, Alibhai SM. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med 2007;147:400411.

    • Search Google Scholar
    • Export Citation
  • 23.

    Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007;25:31583167.

    • Search Google Scholar
    • Export Citation
  • 24.

    Lyman GH, Dale DC, Wolff DA. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol 2010;28:29142924.

    • Search Google Scholar
    • Export Citation
  • 25.

    Lyman GH, Kuderer NM. The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Crit Rev Oncol Hematol 2004;50:129146.

    • Search Google Scholar
    • Export Citation
  • 26.

    Cosler LE, Eldar-Lissai A, Culakova E. Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective. Pharmacoeconomics 2007;25:343351.

    • Search Google Scholar
    • Export Citation
  • 27.

    Doorduijn JK, Buijt I, van der Holt B. Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin’s lymphoma. Haematologica 2004;89:11091117.

    • Search Google Scholar
    • Export Citation
  • 28.

    Eldar-Lissai A, Cosler LE, Culakova E, Lyman GH. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health 2008;11:172179.

    • Search Google Scholar
    • Export Citation
  • 29.

    Numnum TM, Kimball KJ, Rocconi RP. Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma—a cost-effectiveness analysis. Int J Gynecol Cancer 2007;17:10191024.

    • Search Google Scholar
    • Export Citation
  • 30.

    Timmer-Bonte JN, Adang EM, Termeer E. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy. J Clin Oncol 2008;26:290296.

    • Search Google Scholar
    • Export Citation
  • 31.

    Food and Drug Administration. Filgrastim label information. Available at: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=97cc73cc-b5b7-458a-a933-77b00523e193. Accessed May 1, 2013.

    • Search Google Scholar
    • Export Citation
  • 32.

    Food and Drug Administration. Pegfilgrastim label information. Available at: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fdfe5d72-6b80-435a-afa4-c5d74dd852ce. Accessed May 1, 2013.

    • Search Google Scholar
    • Export Citation
  • 33.

    Tigue CC, McKoy JM, Evens AM. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant 2007;40:185192.

    • Search Google Scholar
    • Export Citation
  • 34.

    D’Souza A, Jaiyesimi I, Trainor L, Venuturumili P. Granulocyte colony-stimulating factor administration: adverse events. Transfus Med Rev 2008;22:280290.

    • Search Google Scholar
    • Export Citation
  • 35.

    Adler BK, Salzman DE, Carabasi MH. Fatal sickle cell crisis after granulocyte colony-stimulating factor administration. Blood 2001;97:33133314.

    • Search Google Scholar
    • Export Citation
  • 36.

    Grigg AP. Granulocyte colony-stimulating factor-induced sickle cell crisis and multiorgan dysfunction in a patient with compound heterozygous sickle cell/beta+ thalassemia. Blood 2001;97:39983999.

    • Search Google Scholar
    • Export Citation
  • 37.

    Kang EM, Areman EM, David-Ocampo V. Mobilization, collection, and processing of peripheral blood stem cells in individuals with sickle cell trait. Blood 2002;99:850855.

    • Search Google Scholar
    • Export Citation
  • 38.

    Martin WG, Ristow KM, Habermann TM. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol 2005;23:76147620.

    • Search Google Scholar
    • Export Citation
  • 39.

    Azoulay E, Attalah H, Harf A. Granulocyte colony-stimulating factor or neutrophil-induced pulmonary toxicity: myth or reality? Systematic review of clinical case reports and experimental data. Chest 2001;120:16951701.

    • Search Google Scholar
    • Export Citation
  • 40.

    Evens AM, Cilley J, Ortiz T. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol 2007;137:545552.

    • Search Google Scholar
    • Export Citation
  • 41.

    Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist 2005;10:427437.

  • 42.

    Aslani A, Smith RC, Allen BJ. The predictive value of body protein for chemotherapy-induced toxicity. Cancer 2000;88:796803.

  • 43.

    Chrischilles E, Delgado DJ, Stolshek BS. Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin’s lymphoma. Cancer Control 2002;9:203211.

    • Search Google Scholar
    • Export Citation
  • 44.

    Lyman GH, Dale DC, Friedberg J. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: a nationwide study. J Clin Oncol 2004;22:43024311.

    • Search Google Scholar
    • Export Citation
  • 45.

    Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 2003;98:24022409.

    • Search Google Scholar
    • Export Citation
  • 46.

    Lyman GH, Morrison VA, Dale DC. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin’s lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 2003;44:20692076.

    • Search Google Scholar
    • Export Citation
  • 47.

    Morrison VA, Picozzi V, Scott S. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin’s lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma 2001;2:4756.

    • Search Google Scholar
    • Export Citation
  • 48.

    Lyman GH, Kuderer NM, Crawford J. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 2011;117:19171927.

    • Search Google Scholar
    • Export Citation
  • 49.

    Smith TJ, Khatcheressian J, Lyman GH. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:31873205.

    • Search Google Scholar
    • Export Citation
  • 50.

    Aapro MS, Bohlius J, Cameron DA. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011;47:832.

    • Search Google Scholar
    • Export Citation
  • 51.

    Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004;100:228237.

    • Search Google Scholar
    • Export Citation
  • 52.

    Lyman GH. Risk assessment in oncology clinical practice. From risk factors to risk models. Oncology (Williston Park) 2003;17:813.

  • 53.

    Hirsch BR, Lyman GH. Biosimilars: are they ready for primetime in the United States? J Natl Compr Canc Netw 2011;9:934942; quiz 943.

  • 54.

    Zelenetz AD, Ahmed I, Braud EL. NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Canc Netw 2011;9(Suppl 4):S122.

    • Search Google Scholar
    • Export Citation
  • 55.

    del Giglio A, Eniu A, Ganea-Motan D. XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy. BMC Cancer 2008;8:332.

    • Search Google Scholar
    • Export Citation
  • 56.

    Engert A, Griskevicius L, Zyuzgin Y. XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. Leuk Lymphoma 2009;50:374379.

    • Search Google Scholar
    • Export Citation
  • 57.

    Gatzemeier U, Ciuleanu T, Dediu M. XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy. J Thorac Oncol 2009;4:736740.

    • Search Google Scholar
    • Export Citation
  • 58.

    Engert A, del Giglio A, Bias P. Incidence of febrile neutropenia and myelotoxicity of chemotherapy: a meta-analysis of biosimilar G-CSF studies in breast cancer, lung cancer, and non-Hodgkin’s lymphoma. Onkologie 2009;32:599604.

    • Search Google Scholar
    • Export Citation
  • 59.

    Lubenau H, Bias P, Maly AK. Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial. BioDrugs 2009;23:4351.

    • Search Google Scholar
    • Export Citation
  • 60.

    Lubenau H, Sveikata A, Gumbrevicius G. Bioequivalence of two recombinant granulocyte colony-stimulating factor products after subcutaneous injection in healthy volunteers. Int J Clin Pharmacol Ther 2009;47:275282.

    • Search Google Scholar
    • Export Citation
  • 61.

    American Society of Clinical Oncology. Letter to CMS regarding “Neulasta administered same day as chemotherapy”. 2012. Available at: http://www.asco.org/sites/default/files/letter_to_cms_rac_audit_on_neulasta_110912_lthd.pdf. Accessed May 1, 2013.

    • Search Google Scholar
    • Export Citation
  • 62.

    Schuman SI, Lambrou N, Robson K. Pegfilgrastim dosing on same day as myelosuppressive chemotherapy for ovarian or primary peritoneal cancer. J Support Oncol 2009;7:225228.

    • Search Google Scholar
    • Export Citation
  • 63.

    Whitworth JM, Matthews KS, Shipman KA. The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies. Gynecol Oncol 2009;112:601604.

    • Search Google Scholar
    • Export Citation
  • 64.

    Burris HA, Belani CP, Kaufman PA. Pegfilgrastim on the same day versus next day of chemotherapy in patients with breast cancer, non-small-cell lung cancer, ovarian cancer, and non-hodgkin’s lymphoma: results of four multicenter, double-blind, randomized phase II studies. J Oncol Pract 2010;6:133140.

    • Search Google Scholar
    • Export Citation
  • 65.

    Kaufman PA, Paroly W, Rinaldi D. Randomized double blind phase 2 study evaluating same-day vs. next-day administration of pegfilgrastim with docetaxel, doxorubicin and cyclophosphamide (TAC) in women with early stage and advanced breast cancer [abstract]. Breast Cancer Res Treat 2004;88:Abstract 1054.

    • Search Google Scholar
    • Export Citation
  • 66.

    Saven A, Schwartzberg L, Kaywin P. Randomized, double-blind, phase 2, study evaluating same-day vs next-day administration of pegfilgrastim with R-CHOP in non-Hodgkin’s lymphoma patients [abstract]. J Clin Oncol 2006;24(Suppl 18):Abstract 7570.

    • Search Google Scholar
    • Export Citation
  • 67.

    Belani CP, Ramalingam S, Al-Janadi A. A randomized double-blind phase II study to evaluate same-day vs next-day administration of pegfilgrastim with carboplatin and docetaxel in patients with NSCLC [abstract]. J Clin Oncol 2006;24(Suppl 18):Abstract 7110.

    • Search Google Scholar
    • Export Citation
  • 68.

    Green MD, Koelbl H, Baselga J. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:2935.

    • Search Google Scholar
    • Export Citation
  • 69.

    Watanabe T, Tobinai K, Shibata T. Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin’s lymphoma: JCOG 0203 trial. J Clin Oncol 2011;29:39903998.

    • Search Google Scholar
    • Export Citation
  • 70.

    Hecht JR, Pillai M, Gollard R. A randomized, placebo-controlled phase II study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. Clin Colorectal Cancer 2010;9:95101.

    • Search Google Scholar
    • Export Citation
  • 71.

    Brusamolino E, Rusconi C, Montalbetti L. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica 2006;91:496502.

    • Search Google Scholar
    • Export Citation
  • 72.

    Burstein HJ, Parker LM, Keshaviah A. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol 2005;23:83408347.

    • Search Google Scholar
    • Export Citation
  • 73.

    Jones RL, Walsh G, Ashley S. A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer. Br J Cancer 2009;100:305310.

    • Search Google Scholar
    • Export Citation
  • 74.

    Pirker R, Ulsperger E, Messner J. Achieving full-dose, on-schedule administration of ACE chemotherapy every 14 days for the treatment of patients with extensive small-cell lung cancer. Lung 2006;184:279285.

    • Search Google Scholar
    • Export Citation
  • 75.

    Stull DM, Bilmes R, Kim H, Fichtl R. Comparison of sargramostim and filgrastim in the treatment of chemotherapy-induced neutropenia. Am J Health Syst Pharm 2005;62:8387.

    • Search Google Scholar
    • Export Citation
  • 76.

    Thomas X, Raffoux E, Renneville A. Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF study. Cancer 2010;116:17251732.

    • Search Google Scholar
    • Export Citation
  • 77.

    Thomas X, Raffoux E, Botton S. Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. Leukemia 2007;21:453461.

    • Search Google Scholar
    • Export Citation
  • 78.

    Clark OA, Lyman GH, Castro AA. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 2005;23:41984214.

    • Search Google Scholar
    • Export Citation
  • 79.

    Berghmans T, Paesmans M, Lafitte JJ. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients: a systematic review of the literature with meta-analysis. Support Care Cancer 2002;10:181188.

    • Search Google Scholar
    • Export Citation
  • 80.

    Garcia-Carbonero R, Mayordomo JI, Tornamira MV. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst 2001;93:3138.

    • Search Google Scholar
    • Export Citation
  • 81.

    Johnston E, Crawford J, Blackwell S. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000;18:25222528.

    • Search Google Scholar
    • Export Citation
  • 82.

    Hosing C. Hematopoietic stem cell mobilization with G-CSF. Methods Mol Biol 2012;904:3747.

  • 83.

    Kobbe G, Bruns I, Fenk R. Pegfilgrastim for PBSC mobilization and autologous haematopoietic SCT. Bone Marrow Transplant 2009;43:669677.

  • 84.

    Kroger N, Zeller W, Fehse N. Mobilizing peripheral blood stem cells with high-dose G-CSF alone is as effective as with Dexa-BEAM plus G-CSF in lymphoma patients. Br J Haematol 1998;102:11011106.

    • Search Google Scholar
    • Export Citation
  • 85.

    Barlogie B, Anaissie E, van Rhee F. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007;138:176185.

    • Search Google Scholar
    • Export Citation
  • 86.

    Haynes A, Hunter A, McQuaker G. Engraftment characteristics of peripheral blood stem cells mobilised with cyclophosphamide and the delayed addition of G-CSF. Bone Marrow Transplant 1995;16:359363.

    • Search Google Scholar
    • Export Citation
  • 87.

    Matasar MJ, Czuczman MS, Rodriguez MA. Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. Blood 2013;122:499506.

    • Search Google Scholar
    • Export Citation
  • 88.

    Chaudhary L, Awan F, Cumpston A. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF. J Clin Apher 2013, in press.

    • Search Google Scholar
    • Export Citation
  • 89.

    Dugan MJ, Maziarz RT, Bensinger WI. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin’s lymphoma undergoing stem cell mobilization. Bone Marrow Transplant 2010;45:3947.

    • Search Google Scholar
    • Export Citation
  • 90.

    Gopal AK, Karami M, Mayor J. The effective use of plerixafor as a real-time rescue strategy for patients poorly mobilizing autologous CD34(+) cells. J Clin Apher 2012;27:8187.

    • Search Google Scholar
    • Export Citation
  • 91.

    Milone G, Tripepi G, Martino M. Early measurement of CD34+ cells in peripheral blood after cyclophosphamide and granulocyte colony-stimulating factor treatment predicts later CD34+ mobilisation failure and is a possible criterion for guiding “on demand” use of plerixafor. Blood Transfus 2013;11:94101.

    • Search Google Scholar
    • Export Citation
  • 92.

    Costa LJ, Kramer C, Hogan KR. Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis. Transfusion 2012;52:23752381.

    • Search Google Scholar
    • Export Citation
  • 93.

    Bensinger WI, Weaver CH, Appelbaum FR. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995;85:16551658.

    • Search Google Scholar
    • Export Citation
  • 94.

    Cavallaro AM, Lilleby K, Majolino I. Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant 2000;25:8589.

    • Search Google Scholar
    • Export Citation
  • 95.

    Rinaldi C, Savignano C, Pasca S. Efficacy and safety of peripheral blood stem cell mobilization and collection: a single-center experience in 190 allogeneic donors. Transfusion 2012;52:23872394.

    • Search Google Scholar
    • Export Citation
  • 96.

    Lane TA, Ho AD, Bashey A. Mobilization of blood-derived stem and progenitor cells in normal subjects by granulocyte-macrophage- and granulocyte-colony-stimulating factors. Transfusion 1999;39:3947.

    • Search Google Scholar
    • Export Citation
  • 97.

    Lonial S, Akhtari M, Kaufman J. Mobilization of hematopoietic progenitors from normal donors using the combination of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor results in fewer plasmacytoid dendritic cells in the graft and enhanced donor T cell engraftment with Th1 polarization: results from a randomized clinical trial. Biol Blood Marrow Transplant 2013;19:460467.

    • Search Google Scholar
    • Export Citation
  • 98.

    Sohn SK, Kim JG, Seo KW. GM-CSF-based mobilization effect in normal healthy donors for allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2002;30:8186.

    • Search Google Scholar
    • Export Citation
  • 99.

    Linch DC, Milligan DW, Winfield DA. G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial. Br J Haematol 1997;99:933938.

    • Search Google Scholar
    • Export Citation
  • 100.

    Klumpp TR, Mangan KF, Goldberg SL. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol 1995;13:13231327.

    • Search Google Scholar
    • Export Citation
  • 101.

    Lee SM, Radford JA, Dobson L. Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin’s lymphoma: clinical benefits at no extra cost. Br J Cancer 1998;77:12941299.

    • Search Google Scholar
    • Export Citation
  • 102.

    Spitzer G, Adkins DR, Spencer V. Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit. J Clin Oncol 1994;12:661670.

    • Search Google Scholar
    • Export Citation
  • 103.

    Kawano Y, Takaue Y, Mimaya J. Marginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children: results of a prospective randomized trial. The Japanese Cooperative Study Group of PBSCT. Blood 1998;92:40404046.

    • Search Google Scholar
    • Export Citation
  • 104.

    Castagna L, Bramanti S, Levis A. Pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell support. Ann Oncol 2010;21:14821485.

    • Search Google Scholar
    • Export Citation
  • 105.

    Ziakas PD, Kourbeti IS. Pegfilgrastim vs. filgrastim for supportive care after autologous stem cell transplantation: can we decide? Clin Transplant 2012;26:1622.

    • Search Google Scholar
    • Export Citation
  • 106.

    Battiwalla M, McCarthy PL. Filgrastim support in allogeneic HSCT for myeloid malignancies: a review of the role of G-CSF and the implications for current practice. Bone Marrow Transplant 2009;43:351356.

    • Search Google Scholar
    • Export Citation
  • 107.

    Nemunaitis J, Rabinowe SN, Singer JW. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991;324:17731778.

    • Search Google Scholar
    • Export Citation
  • 108.

    Ippoliti C, Przepiorka D, Giralt S. Low-dose non-glycosylated rhGM-CSF is effective for the treatment of delayed hematopoietic recovery after autologous marrow or peripheral blood stem cell transplantation. Bone Marrow Transplant 1993;11:5559.

    • Search Google Scholar
    • Export Citation
  • 109.

    Dale DC, Bonilla MA, Davis MW. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 1993;81:24962502.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 996 585 35
PDF Downloads 134 84 5
EPUB Downloads 0 0 0